TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03332992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viral changes
Description: Telephone script language provided pre-questions regarding the fact that influenza viruses change each year

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viral changes
Description: Telephone script language provided pre-questions regarding the fact that influenza viruses change each year

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viral changes
Description: Telephone script language provided pre-questions regarding the fact that influenza viruses change each year

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protect others
Description: Telephone script language provided pre-questions emphasizing the need to protect vulnerable others

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protect others
Description: Telephone script language provided pre-questions emphasizing the need to protect vulnerable others

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protect others
Description: Telephone script language provided pre-questions emphasizing the need to protect vulnerable others

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General intentions
Description: Question language asking about general interest in getting influenza vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General intentions
Description: Question language asking about general interest in getting influenza vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intentions
Description: Question language asking individual to make specific plans to be vaccinated

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intentions
Description: Question language asking individual to make specific plans to be vaccinated

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accountability
Description: Question language asking individual whether their care team can learn about their vaccination intentions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accountability
Description: Question language asking individual whether their care team can learn about their vaccination intentions
Study: NCT04164056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: deep brain stimulation on the hippocampus or the anterior nucleus of the thalamus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Description: deep brain stimulation on the hippocampus or the anterior nucleus of the thalamus
Study: NCT04446078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK- acrylic resin prosthesis supported by 4 dental implants
Description: Patients rehabilitated for edentulism of one or both arches through an implant supported fixed prosthesis
Study: NCT00747396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foster Care Placement
Description: A group of children living in institutions in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and trained in Romanian. Before placement, foster parents visited their children to begin developing a relationship with the child. Hired foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Foster parents were invited to participate in a support group organized by social workers. Project social workers consulted weekly with US staff experienced in dealing with young children in foster care.
Study: NCT05098158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-pharmacological pain treatment
Description: Participant selects from telehealth consultation on massage therapy, yoga therapy, chiropractic and physical therapies.
Study: NCT03677817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: regimen of lidocaine administration of 1,5 mg/kg, IV bolus, followed by continuous infusion at 3,0 mg/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
Study: NCT03531333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided surgery.
Description: during surgery, the neurosurgeon will acquire ultrasound guided images (fused with the standard neuronavigation system) to evaluate the progress of tumor resection.
Study: NCT03365804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Brace
Description: All subjects' body shape will be scanned to generate sterolithography (STL) files for 3D printing.
Study: NCT01286948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)
Description: This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)
Description: This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated.
Study: NCT01524367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
Study: NCT04020146

Intervention type: OTHER
Intervention: Gingival biopsies
Description: Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.

Intervention type: OTHER
Intervention: Gingival biopsies
Description: Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.

Intervention type: OTHER
Intervention: Gingival biopsies
Description: Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.
Study: NCT01434641

Intervention type: OTHER
Group type: OTHER
Intervention: low-dose stress MPI SPECT
Description: novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
Study: NCT02841319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercises using Hand Tutor
Description: Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
Study: NCT01146249

Intervention type: OTHER
Intervention: Balance assessment under sensory stimulation
Description: Balance assessment under sensory stimulation

Intervention type: OTHER
Intervention: Balance assessment under sensory stimulation
Description: Balance assessment under sensory stimulation

Intervention type: OTHER
Intervention: Balance assessment under sensory stimulation
Description: Balance assessment under sensory stimulation

Intervention type: OTHER
Intervention: Balance assessment under sensory stimulation
Description: Balance assessment under sensory stimulation

Intervention type: OTHER
Intervention: Balance assessment under sensory stimulation
Description: Balance assessment under sensory stimulation
Study: NCT02568345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex ED90
Description: The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.~In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg.
Study: NCT00848250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin Converting Enzyme Inhibitor
Description: Patients randomized to this group will continue their current dose of ACE inhibitors until surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No ACE Inhibitor
Description: Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
Study: NCT03512977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sphenopalatine ganglion block
Description: the intervention will be performed on sitting position. Lidocaine 2% viscous (0.5ml) will be apply on cotton swab sticks and one will be gently inserted into nostril, along the floor of the nose. Stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab stick will be left undisturbed for 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline
Study: NCT03085147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
Study: NCT02075749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: licorice mucoadhesive films
Description: 30 patients received licorice mucoadhesive films
Study: NCT00960128

Intervention type: DRUG
Intervention: somatropin
Description: The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.

Intervention type: DRUG
Intervention: somatropin
Description: The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
Study: NCT01842841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Description: 15-60 U/kg, EOW
Study: NCT04020094

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury
Description: Cycle= 21 days. Neoadjuvant Therapy: Treatment will be given for 2 neoadjuvant cycles. MVA-BN-Brachyury will be administered as intratumoral injection on Day 1 of each of 2 neoadjuvant cycles. PROSTVAC-V will be administered as a subq injection on Day 1 of Cycle 1 (the first neoadjuvant cycle) and PROSTVAC-F will be administered as a subq injection on Day 1 of Cycle 2 (the second neoadjuvant cycle). Atezolizumab will be given as an infusion on Day 1 of each 2 neoadjuvant cycles.~MVA-BN-Brachyury will be injected intratumorally into the prostate. Injections will target PI-RADS 4 and 5 lesions.~Surgery: Patients will undergo SOC radical prostatectomy Adjuvant Therapy: Systemic treatment with atezolizumab and PROSTVAC-F will be reinitiated between 3 to 8 weeks after surgery and will continue for an additional 6 cycles. PROSTVAC-F will be given as a subq injection on Day 1 of each cycle. Atezolizumab will be given as an infusion on Day 1 of each cycle.
Study: NCT00721422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: 50 mg (two 25 mg capsules), single, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: 50 mg (two 25 mg capsules), single, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: 50 mg (two 25 mg capsules), single, oral dose
Study: NCT04353102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH002
Description: YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.
Study: NCT03385512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPEN High Touch
Description: This arm will contain three components: (a) a pre-visit questionnaire delivered through the patient portal of the EHR, asking patients what they most want to discuss with their physician in the upcoming visit; (b) an animated video for patients providing coaching on how to best prepare for their upcoming visits and get the most from the visits; and (c) Standardized Patient Instructor (SPI) providing communication coaching for physicians on how to incorporate what matter most to patients in the visit, with empathy, and clarity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPEN High Tech
Description: The patient components of the intervention will be identical to the patient components of the High Touch arm (i.e., the pre-visit survey and patient coaching video). The difference will be in the PCP training: we will replace the in-person SPI with a mobile app program.
Study: NCT04075019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Raising Healthy Children intervention, including teacher training, child skill development, and parent training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Raising Healthy Children intervention, including teacher training, child skill development, and parent training
Study: NCT04209335

Intervention type: OTHER
Group type: OTHER
Intervention: isometric core muscle endurance testing
Description: holding previously described isometric positions until fatigue
Study: NCT03987594

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transurethral fulguration of the Hunner lesion
Description: Hunner lesion of the bladder is fulgurated with electronic surgical device under cystoscopic inspection. For the intervention, general or spinal anesthesia is required.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion
Description: Prior to Hunner lesion fulguration, bladder hydrodistension is performed for 8 minutes at pressure of 80cmH2O. And then transurethral fulguration is performed on the Hunner lesion.
Study: NCT03346252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin type A
Description: All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.~In addition, they will undergo 3 cycles of treatment, each 12 weeks apart.
Study: NCT03407521

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: induction of abortion using misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: induction of abortion using misoprostol
Study: NCT03385512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASK Poster in Exam Rooms
Description: This arm is intended to activate patients by encouraging them to ask three questions during their primary care visit: (1) What are my options? (2) What are the possible benefits and risks of each option? (3) How likely are the benefits and risks of each option to occur to me? This will involve placing posters with these questions in all exam rooms used by providers in clinics randomized to the ASK arm of the trial.
Study: NCT03407521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isosorbide mononitrate
Description: isosorbide mononitrate
Study: NCT00721422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: 50 mg (two 25 mg capsules), single, oral dose
Study: NCT02383680

Intervention type: BIOLOGICAL
Intervention: Yellow Fever Vaccination
Description: The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.

Intervention type: BIOLOGICAL
Intervention: Yellow Fever Vaccination
Description: The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.
Study: NCT01902953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek and VBD Sln dissection
Description: See detailed description of study design
Study: NCT04060264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-148
Description: Active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).~QW - once weekly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCD-148
Description: Active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).~QW - once weekly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Soliris
Description: Active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).
Study: NCT02902913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D2i2
Description: Oleocanthal provided in a 2:1 ratio compared to oleacein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D2i0.5
Description: Oleocanthal provided in a 1:2 ratio compared to oleacein
Study: NCT03407521

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02677649

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cranberry
Description: the effect of cranberry on the gut microbiota

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the effect of placebo on the gut microbiota
Study: NCT04627480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher Wallace Neurostimulation Device
Description: a Cranial Electrotherapy Stimulator Device (CES).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fisher Wallace Neurostimulation Device
Description: a Cranial Electrotherapy Stimulator Device (CES).
Study: NCT02114957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0
Study: NCT01906086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: life style intervention
Study: NCT04715997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-19N
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT02409394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Study: NCT02577341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and cisplatin
Description: Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: daily RT to the chest
Description: Patients received daily RT to the chest

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: daily RT to the chest
Description: Patients received daily RT to the chest
Study: NCT03647631

Intervention type: PROCEDURE
Intervention: sentinel lymph node biopsy
Description: Authors discuss a possible usefulness of SNLB for staging and diagnosis in porocarcinoma.
Study: NCT05990244

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRE and routine MRI
Study: NCT02537873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine Intravenous (IV)
Description: Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine Intravenous (IV)
Description: Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Dextrose in gelatin capsule